These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 19391415)

  • 41. EMANCIPATE study: drawing conclusions may be difficult in the absence of fundamental information.
    Galmiche JP
    Eur J Gastroenterol Hepatol; 2008 Feb; 20(2):151-2; author reply 153-5. PubMed ID: 18188040
    [No Abstract]   [Full Text] [Related]  

  • 42. Review article: pH, healing and symptom relief with rabeprazole treatment in acid-related disorders.
    Robinson M
    Aliment Pharmacol Ther; 2004 Nov; 20 Suppl 6():30-7. PubMed ID: 15496216
    [TBL] [Abstract][Full Text] [Related]  

  • 43. EMANCIPATE versus EXPO: different results can be explained by differing study designs.
    Labenz J
    Eur J Gastroenterol Hepatol; 2008 Feb; 20(2):152; author reply 153-5. PubMed ID: 18188041
    [No Abstract]   [Full Text] [Related]  

  • 44. [Using sunpraz in GERD].
    Antipina TV; Merkulova SA; Dobrochasova NM; Guseva MV; Tkacheva AG
    Eksp Klin Gastroenterol; 2008; (3):94-6. PubMed ID: 19145888
    [No Abstract]   [Full Text] [Related]  

  • 45. Cost effectiveness of treatment for gastro-oesophageal reflux disease in clinical practice: a clinical database analysis.
    Eggleston A; Wigerinck A; Huijghebaert S; Dubois D; Haycox A
    Gut; 1998 Jan; 42(1):13-6. PubMed ID: 9505878
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [When sour does not make merry at all . Fast relief for patients with reflux].
    MMW Fortschr Med; 2003 Apr; 145(15):64. PubMed ID: 15104274
    [No Abstract]   [Full Text] [Related]  

  • 47. Efficacy and safety of pantoprazole versus ranitidine in the treatment of patients with symptomatic gastroesophageal reflux disease.
    van Zyl J; van Rensburg C; Vieweg W; Fischer R
    Digestion; 2004; 70(1):61-9. PubMed ID: 15297779
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Modern approach to the therapy of gastroesophageal reflux disease].
    Ivashkin VT; Trukhmanov AS
    Voen Med Zh; 2003 Oct; 324(10):26-34. PubMed ID: 14671892
    [No Abstract]   [Full Text] [Related]  

  • 49. [Treatment of reflux disease. An international consensus conference put things in its place].
    Weber R
    Rev Med Suisse Romande; 2003 Sep; 123(9):3p. PubMed ID: 15095598
    [No Abstract]   [Full Text] [Related]  

  • 50. Rabeprazole.
    Med Lett Drugs Ther; 1999 Nov; 41(1066):110-2. PubMed ID: 10987010
    [No Abstract]   [Full Text] [Related]  

  • 51. Severe gastro-oesophageal reflux disease.
    Gonçalves AR
    Clin Drug Investig; 2009; 29 Suppl 2():13-5. PubMed ID: 19938881
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cost effectiveness of medical versus surgical treatment in patients with severe or refractory gastroesophageal reflux disease in the Netherlands.
    Van Den Boom G; Go PM; Hameeteman W; Dallemagne B; Ament AJ
    Scand J Gastroenterol; 1996 Jan; 31(1):1-9. PubMed ID: 8927933
    [TBL] [Abstract][Full Text] [Related]  

  • 53. On-demand therapy with pantoprazole 20 mg as effective long-term management of reflux disease in patients with mild GERD: the ORION trial.
    Scholten T; Dekkers CP; Schütze K; Körner T; Bohuschke M; Gatz G
    Digestion; 2005; 72(2-3):76-85. PubMed ID: 16113546
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Results of the treatment of duodenal ulcer associated with Helicobacter pylori and combined with gastroesophageal reflux disease].
    Vasil'ev IuV; Nikol'skaia KA
    Eksp Klin Gastroenterol; 2005; (6):61-4. PubMed ID: 17378390
    [No Abstract]   [Full Text] [Related]  

  • 55. Cost effectiveness of rabeprazole versus generic ranitidine for symptom resolution in patients with erosive esophagitis.
    Ofman JJ; Yamashita BD; Siddique RM; Larson LR; Willian MK
    Am J Manag Care; 2000 Aug; 6(8):905-16. PubMed ID: 11186502
    [TBL] [Abstract][Full Text] [Related]  

  • 56. BUDGET IMPACT ANALYSIS OF USING OMEPRAZOLE IMMEDIATE-RELEASE ORAL SUSPENSION IN REPLACE OF INTRAVENOUS PANTOPRAZOLE IN CRITICALLY ILL PATIENTS.
    Foroutan N; Fahimi F; Dabiri Y; Foroutan A; Habibi M; Salamzadeh J
    J Popul Ther Clin Pharmacol; 2015 Dec; 22(3):e292-e302. PubMed ID: 28414416
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Modeling the cost-effectiveness of ilaprazole versus omeprazole for the treatment of newly diagnosed duodenal ulcer patients in China.
    Xuan JW; Song RL; Xu GX; Lu WQ; Lu YJ; Liu Z
    J Med Econ; 2016 Nov; 19(11):1056-1060. PubMed ID: 27223846
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Counting the cost of proton pump inhibitors.
    Moayyedi P
    Gut; 2001 Oct; 49(4):462-3. PubMed ID: 11559638
    [No Abstract]   [Full Text] [Related]  

  • 59. [Why some proton pump inhibitors are more equal than others].
    Otten MH; Lekkerkerker JF; Mulder CJ
    Ned Tijdschr Geneeskd; 2009; 153():B414. PubMed ID: 19785839
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Quality of life and cost of therapy in reflux disease.
    Glise H
    Scand J Gastroenterol Suppl; 1995; 210():38-42. PubMed ID: 8578204
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.